Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases.
Business Model:
Revenue: $27.5B
Employees: 10,001-999,999
Address: 333 Lakeside Drive
City: Foster City
State: CA
Zip: 94404
Country: US
Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases.
Contact Phone:
+16505743000
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
10/27/2017
Ticker Symbol:
GILD
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2023 | Helping Everyone Receive Ongoing and Effective Support | Grant | - |
2/2023 | Nueva vida | Grant | - |
3/2021 | Vaccitech | Series B | 168M |
6/2018 | Precision BioSciences | Series B | 0 |
9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
1/2018 | Tmunity Therapeutics | Series A | 0 |
5/2022 | Exavir Therapeutics | Seed | 4M |
10/2018 | Glympse Bio | Series A | 0 |
6/2020 | Pionyr Immunotherapeutics | Corporate Round | 275M |
3/2023 | Alliance of AIDS Services | Grant | - |
3/2023 | Power Safe Place Resource Center of Virginia | Grant | - |
3/2023 | Pierce County AIDS Foundation | Grant | - |
3/2023 | My Brother&s;s Keeper | Grant | - |
3/2023 | Yale Cancer Center | Venture Round | - |
5/2022 | Curebase | Series B | 0 |
8/2020 | Tango Therapeutics | Venture Round | 50M |
3/2023 | Central Illinois Friends | Grant | - |
6/2020 | Goldfinch Biopharma | Series B | 100M |
12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
6/2021 | Lyndra Therapeutics | Series C | 0 |
4/2018 | Allogene | Series A | 0 |
5/2019 | AlloVir | Series B | 120M |
7/2022 | AlloVir | Post-IPO Equity | 0 |
1/2022 | Kyverna Therapeutics | Series B | 0 |
8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
2/2019 | Lyndra Therapeutics | Series B | 0 |
10/2019 | Tmunity Therapeutics | Series B | 0 |
7/2020 | Glympse Bio | Series B | 46.7M |
4/2018 | Tmunity Therapeutics | Series A | 0 |
5/2019 | Goldfinch Biopharma | Corporate Round | 55M |
2/2021 | Arcus Biosciences | Post-IPO Equity | 220.3M |
11/2021 | Destination Tomorrow | Grant | 1M |
7/2019 | Galapagos | Post-IPO Equity | 5.1B |
3/2023 | Empowering Transgender Services | Grant | - |
2/2023 | Young Survival Coalition | Grant | - |
5/2020 | Arcus Biosciences | Post-IPO Equity | 200M |
7/2020 | Tizona Therapeutics | Corporate Round | 300M |
2/2020 | Vineti | Series C | 35M |
11/2019 | National AIDS Memorial | Grant | 24M |
4/2006 | Corus Pharma | Venture Round | 25M |
3/2023 | Empowering Transgender Services | Grant | - |
3/2023 | Alliance of AIDS Services | Grant | - |
3/2023 | Power Safe Place Resource Center of Virginia | Grant | - |
3/2023 | Pierce County AIDS Foundation | Grant | - |
3/2023 | Helping Everyone Receive Ongoing and Effective Support | Grant | - |
3/2023 | My Brother&s;s Keeper | Grant | - |
3/2023 | Central Illinois Friends | Grant | - |
3/2023 | Yale Cancer Center | Venture Round | - |
2/2023 | Nueva vida | Grant | - |
2/2023 | Young Survival Coalition | Grant | - |
Announced Date | Name | Price |
---|---|---|
5/2023 | XinThera | |
8/2022 | MiroBio | |
12/2020 | MYR GmbH | |
9/2020 | Immunomedics | |
3/2020 | Forty Seven | |
12/2017 | Cell Design Labs | |
8/2017 | Kite Pharma | |
4/2016 | Nimbus Apollo | |
5/2015 | Epitherapeutics | |
1/2015 | Phenex Pharmaceuticals |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|